Showing results (511-520 of 587) with videos related to
Sort By:
Pageof 59
Nature Medicine|February 4, 2026
Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trialBenjamin Besse, Jessica J Lin, Lyudmila Bazhenova, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.Molecular Cancer|June 29, 2026
A plasma proteomic signature of cancer-related sarcopenia implicates the IGFBP axis in muscle dysfunctionFilippo Gustavo Dall'Olio, Wael Salem Zrafi, Xinran Song, et al.The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2025
Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 TrialDavid Planchard, Hye Ryun Kim, Thatthan Suksombooncharoen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerDavid R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.Lung Cancer (Amsterdam, Netherlands)|December 20, 2024
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancerIlias Houda, Idris Bahce, Chris Dickhoff, et al.Therapeutic Advances in Medical Oncology|June 30, 2025
Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study)Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, et al.European Journal of Cancer (Oxford, England : 1990)|August 23, 2021
Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control studyCharlotte Cabanié, Samy Ammari, Sophie Hans, et al.Pageof 59